Patents by Inventor Jason Matthew Rohde

Jason Matthew Rohde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer
    Patent number: 10836759
    Abstract: A compound of Formula II or a pharmaceutically acceptable salt thereof, wherein CyN is a cyclic amine group bound via a nitrogen atom; X is C or N; R1 and R2 are each independently a halogen, CN, CF3, CHF2, CH2F, a C1-C10alkyl group, a C1-C10alkoxy group, a di(C1-C5alkyl)amino; m and n are each independently 1, 2, or 3, and represents either a single bond or a double bond, wherein the racemic mixture of 3-(4-(4-chlorophenyl)thiazol-2-yl)-1-(2-ethyl-5-methoxyphenyl)-6-(2-methylprop-1-en-1-yl)-5-(piperazine-1-carbonyl)pyridin-2(1H)-one atropisomers is excluded.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: November 17, 2020
    Assignees: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Matthew Brian Boxer, Xiaodong Wang, Kyle Ryan Brimacombe, Mindy Irene Emily Davis, Yuhong Fang, Matthew Hall, Ajit Jadhav, Surendra Karavadhi, Li Liu, Natalia Martinez, Andrew Louis McIver, Rajan Pragani, Jason Matthew Rohde, Anton Simeonov, Wei Zhao, Min Shen
  • Mutant IDH1 inhibitors useful for treating cancer
    Patent number: 10703746
    Abstract: Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: July 7, 2020
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: Matthew Brian Boxer, Jason Matthew Rohde, Rajan Pragani, Li Liu, Mindy Irene Emily Davis, Kyle Ryan Brimacombe, Min Shen, Anton Simeonov, Surendra Karavadhi, Daniel Jason Urban, Ajit Jadhav, Xiaodong Wang, Andrew Louis McIver
  • THIAZOLE DERIVATIVES USEFUL AS MUTANT IDH1 INHIBITORS FOR TREATING CANCER
    Publication number: 20190241551
    Abstract: A compound of Formula II or a pharmaceutically acceptable salt thereof, wherein CyN is a cyclic amine group bound via a nitrogen atom; X is C or N; R1 and R2 are each independently a halogen, CN, CF3, CHF2, CH2F, a C1-C10alkyl group, a C1-C10alkoxy group, a di(C1-C5alkyl)amino; m and n are each independently 1, 2, or 3, and represents either a single bond or a double bond, wherein the racemic mixture of 3-(4-(4-chlorophenyl)thiazol-2-yl)-1-(2-ethyl-5-methoxyphenyl)-6-(2-methylprop-1-en-1-yl)-5-(piperazine-1-carbonyl)pyridin-2(1H)-one atropisomers is excluded.
    Type: Application
    Filed: June 21, 2017
    Publication date: August 8, 2019
    Inventors: Matthew Brian BOXER, Xiaodong WANG, Kyle Ryan BRIMACOMBE, Mindy Irene Emily DAVIS, Yuhong FANG, Matthew HALL, Ajit JADHAV, Surendra KARAVADHI, Li LIU, Natalia MARTINEZ, Andrew Louis MCIVER, Rajan PRAGANI, Jason Matthew ROHDE, Anton SIMEONOV, Wei ZHAO, Min SHEN
  • MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER
    Publication number: 20190071434
    Abstract: Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.
    Type: Application
    Filed: December 22, 2015
    Publication date: March 7, 2019
    Inventors: Matthew Brian Boxer, Jason Matthew Rohde, Rajan Pragani, LI Liu, Mindy Irene Emily Davis, Kyle Ryan Brimacombe, Min Shen, Anton Simeonov, Surendra Karavadhi, Daniel Jason Urban, Ajit Jadhav, Xiaodong Wang, Andrew Louis McIver